These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22276174)

  • 1. Immunogenic comparison of chimeric adenovirus 5/35 vector carrying optimized human immunodeficiency virus clade C genes and various promoters.
    Shoji M; Yoshizaki S; Mizuguchi H; Okuda K; Shimada M
    PLoS One; 2012; 7(1):e30302. PubMed ID: 22276174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
    Xin KQ; Sekimoto Y; Takahashi T; Mizuguchi H; Ichino M; Yoshida A; Okuda K
    Vaccine; 2007 May; 25(19):3809-15. PubMed ID: 17386962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes.
    Zhao C; Crews CJ; Derdeyn CA; Blackwell JL
    J Virol Methods; 2009 Sep; 160(1-2):101-10. PubMed ID: 19409930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
    Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
    J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunogenicity of a chimeric adenovirus type 5 vector with type 35 fiber containing HIV-1 gag in mice].
    Liu XL; Yu SQ; Feng X; Wang XL; Liu HM; Zhang XM; Li HX; Zhou L; Li ZL; Zheng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):5-7. PubMed ID: 17429520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
    Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.
    McGettigan JP; Sarma S; Orenstein JM; Pomerantz RJ; Schnell MJ
    J Virol; 2001 Sep; 75(18):8724-32. PubMed ID: 11507217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budding and secretion of HIV Gag-Env virus-like particles from recombinant human adenovirus infected cells.
    Luo L; Li Y; Yong Kang C
    Virus Res; 2003 Mar; 92(1):75-82. PubMed ID: 12606078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys.
    Prevec L; Christie BS; Laurie KE; Bailey MM; Graham FL; Rosenthal KL
    J Acquir Immune Defic Syndr (1988); 1991; 4(6):568-76. PubMed ID: 1902514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
    Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
    Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
    Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
    J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
    Deml L; Bojak A; Steck S; Graf M; Wild J; Schirmbeck R; Wolf H; Wagner R
    J Virol; 2001 Nov; 75(22):10991-1001. PubMed ID: 11602739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
    Ding SF; Lombardi R; Nazari R; Joshi S
    Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
    Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
    J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrastructural characterization of human immunodeficiency virus type 1 Gag-containing particles assembled in a recombinant adenovirus vector system.
    Vernon SK; Murthy S; Wilhelm J; Chanda PK; Kalyan N; Lee SG; Hung PP
    J Gen Virol; 1991 Jun; 72 ( Pt 6)():1243-51. PubMed ID: 2045790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.
    Wagner R; Graf M; Bieler K; Wolf H; Grunwald T; Foley P; Uberla K
    Hum Gene Ther; 2000 Nov; 11(17):2403-13. PubMed ID: 11096444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant.
    Huang Y; Chen Z; Zhang W; Gurner D; Song Y; Gardiner DF; Ho DD
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):403-11. PubMed ID: 18209683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.
    Buffa V; Negri DRM; Leone P; Bona R; Borghi M; Bacigalupo I; Carlei D; Sgadari C; Ensoli B; Cara A
    J Gen Virol; 2006 Jun; 87(Pt 6):1625-1634. PubMed ID: 16690927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.